Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q38352305

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.

@en

type

Item

label

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.

@en

prefLabel

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.

@en

P1476

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.

@en

P2093

Hirotaka Iwase

http://www.w3.org/2001/XMLSchema#string

Yutaka Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Combination anastrozole and fulvestrant in metastatic breast cancer

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.

New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer

Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents.

P2888

s10147-015-0793-8

P304

253-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S10147-015-0793-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272188708

http://www.w3.org/2001/XMLSchema#string

P698

25673474

http://www.w3.org/2001/XMLSchema#string